Steven E. Lufkin

Chief Executive Officer at SeLux Diagnostics, Inc.

61 year

Health Technology

Profile

Steven E.
Lufkin is currently the Chief Executive Officer & Director at SeLux Diagnostics, Inc. He was previously the General Manager at ERBA Diagnostics, Inc. for a brief period in 2010.

Steven E. Lufkin active positions

Companies	Position	Start
SeLux Diagnostics, Inc. SeLux Diagnostics, Inc. Medical SpecialtiesHealth Technology SeLux Diagnostics, Inc. develops universal synthetic amplifier technology equipment. The firm offers Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. The company was founded by Eric Stern and Aleksander Vacic in 2014 and is headquartered in Charlestown, MA.	Chief Executive Officer	2016-12-31

All active positions of Steven E. Lufkin

Former positions of Steven E. Lufkin

Companies	Position	End
ERBA DIAGNOSTICS, INC.	Corporate Officer/Principal	2010-09-29

See the detail of Steven E. Lufkin's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Steven E. Lufkin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. Medical SpecialtiesHealth Technology ERBA Diagnostics, Inc. was engaged in manufacturing and marketing of proprietary diagnostic reagents, test kits and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes, and infectious diseases. The company was founded on March 14, 2001 and was headquartered in Miami Lakes, FL.	Health Technology
SeLux Diagnostics, Inc. SeLux Diagnostics, Inc. Medical SpecialtiesHealth Technology SeLux Diagnostics, Inc. develops universal synthetic amplifier technology equipment. The firm offers Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. The company was founded by Eric Stern and Aleksander Vacic in 2014 and is headquartered in Charlestown, MA.	Health Technology